YUKI GOSEI KOGYO CO.,LTD. Logo

YUKI GOSEI KOGYO CO.,LTD.

Manufactures fine chemicals, amino acids, and APIs via organic synthesis for global industries.

4531 | T

Overview

Corporate Details

ISIN(s):
JP3946400003
LEI:
Country:
Japan
Address:
中央区日本橋人形町三丁目10番4号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Yuki Gosei Kogyo Co., Ltd. is a chemical manufacturing company established in 1947. Specializing in the field of organic synthesis, the company engages in the research, development, manufacturing, and marketing of fine chemical products. Its core product portfolio includes amino acids (such as Glycine), pharmaceuticals, active pharmaceutical ingredients (APIs), and various chemical intermediates. Utilizing its unique and proprietary technologies, Yuki Gosei Kogyo serves both Japanese and international markets, providing high-quality products for various industrial applications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 02:35
Report Publication Announcement
確認書
Japanese 8.9 KB
2025-11-13 02:32
Interim Report
半期報告書-第106期(2025/04/01-2026/03/31)
Japanese 184.9 KB
2025-06-24 04:13
Post-Annual General Meeting Information
臨時報告書
Japanese 26.5 KB
2025-06-19 06:08
Governance Information
内部統制報告書-第105期(2024/04/01-2025/03/31)
Japanese 23.0 KB
2025-06-19 06:07
Registration Form
確認書
Japanese 8.8 KB
2025-06-19 06:05
Annual Report
有価証券報告書-第105期(2024/04/01-2025/03/31)
Japanese 724.5 KB
2025-01-08 02:05
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.8 KB
2024-12-04 02:01
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.8 KB
2024-11-13 02:17
Interim Report
確認書
Japanese 8.8 KB
2024-11-13 02:15
Interim Report
半期報告書-第105期(2024/04/01-2025/03/31)
Japanese 188.9 KB
2024-11-06 02:32
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.3 KB
2024-10-03 09:16
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.1 KB
2024-09-04 03:21
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.8 KB
2024-08-06 04:12
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.7 KB
2024-06-25 02:36
Post-Annual General Meeting Information
臨時報告書
Japanese 26.8 KB

Automate Your Workflow. Get a real-time feed of all YUKI GOSEI KOGYO CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for YUKI GOSEI KOGYO CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for YUKI GOSEI KOGYO CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Bioengineering solutions to accelerate life sciences research, from gene synthesis to cell lines.
South Korea
355690
aTYR PHARMA INC Logo
Developing novel medicines for fibrosis and inflammation using tRNA synthetase biology.
United States of America
ATYR
Aura Biosciences, Inc. Logo
Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.
United States of America
AURA
Aurinia Pharmaceuticals Inc. Logo
Biopharma developing therapies for autoimmune and kidney diseases like lupus nephritis.
United States of America
AUPH
AURORA CANNABIS INC Logo
A global producer and seller of medical and recreational cannabis and derivative products.
United States of America
ACB
Autolus Therapeutics plc Logo
Develops programmed CAR T-cell therapies for cancer and autoimmune diseases.
United States of America
AUTL
AVADEL PHARMACEUTICALS PLC Logo
Develops once-at-bedtime therapies for adults with narcolepsy using innovative drug delivery.
United States of America
AVDL
Avidity Biosciences, Inc. Logo
Pioneering targeted RNA therapies that treat the root cause of rare muscle diseases.
United States of America
RNA
Axsome Therapeutics, Inc. Logo
Biopharma company developing novel therapies for central nervous system (CNS) conditions.
United States of America
AXSM
AYTU BIOPHARMA, INC Logo
Specialty pharma advancing innovative medicines for CNS diseases like MDD and ADHD.
United States of America
AYTU

Talk to a Data Expert

Have a question? We'll get back to you promptly.